Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
University of California Irvine
Search grants from University of California Irvine
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Fred Hutchinson Cancer Research Center
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Pediatric Brain Tumor ConsortiumA multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors.
Bio-electrochemical detectors for in vivo continuous monitoring
Genomic approaches to cardiometabolic risk and treatment in HIV
Poliovirus Using Infectious Viral Cdna Clone
Symposium: "The Biology and Conservation of Epiphytes;" Sarasota, FL; May 5-8, 1991
Recently added grants:
Role of gasdermin D in bone resorption
Medium-chain acyl-coenzyme A dehydrogenase as an essential feeder of glioblastoma multiforme
Regulation of TAL1/SCL in T-Cell Leukemia
Bionanotechnology approach for treatment of lung cancer
A personalized approach to skin cancer prevention among adolescents
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CA075019-004
Application #
6688678
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2002
Total Cost
Indirect Cost
Institution
Name
University of California Irvine
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2003
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
NIH 2002
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
Publications
Beeram, M; Tan, Q-T N; Tekmal, R R et al.
(2007)
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Ann Oncol 18:1323-8
Comments
Be the first to comment on this grant